Premium
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
Author(s) -
Aalipour Amin,
Advani Ranjana H.
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12573
Subject(s) - bruton's tyrosine kinase , ibrutinib , dasatinib , tyrosine kinase , cancer research , b cell , b cell receptor , medicine , pharmacology , immunology , biology , leukemia , receptor , chronic lymphocytic leukemia , antibody
Summary Constitutive or aberrant signalling of the B cell receptor signalling cascade has been implicated in the propagation and maintenance of a variety of B cell malignancies. Small molecule inhibitors of B ruton tyrosine kinase ( BTK ), a protein early in this cascade and specifically expressed in B cells, have emerged as a new class of targeted agents. There are several BTK inhibitors, including ONO ‐ WG ‐307, LFM ‐ A 13, dasatinib, CC ‐292, and PCI ‐32765 (ibrutinib), in preclinical and/or clinical development of which ibrutinib is currently in phase III trials. Recent clinical data suggest significant activity of ibrutinib as a first in class oral inhibitor of BTK . This review provides an overview of ongoing clinical studies of BTK inhibitors.